Radiotherapy of solitary plasmacytoma

Krause, Sonja; Hillengaß, Jens; Goldschmidt, Hartmut; Debus, Jürgen; Neuhof, Dirk

doi:10.1007/s00277-011-1190-7

Cited by 26 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous reports, on outcome for patients with plasmacytoma, mostly with limited patient numbers, follow‐up time has been shorter than in the present study. While some series show no significant difference between SBP and SEP regarding OS others shows favorable OS for SEP . Although the rate of progression to MM in our study was much higher in the SBP group, we did not find a significant difference in OS between the 2 groups.…”

Section: Discussioncontrasting

confidence: 84%

Long‐term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population‐based, single‐center study with median follow‐up of 13.7 years

Barzenje

Kolstad

Holte

2017

Hematological Oncology

View full text Add to dashboard Cite

In this single-center, population-based, and retrospective study, we analyzed the outcome of 49 patients with solitary bone plasmacytoma (SBP) and 28 patients with solitary extramedullary plasmacytoma (SEP), all treated with radiotherapy. Laminectomy was performed in 18/30 SBP patients with vertebral involvement and tumour resection in 10 SEP patients. Overall survival and cause of death for each patient were compared to 5 sex-, age-, and residency-matched individuals from the normal population. Response (complete and partial) was achieved in 94% of SBP and 96% of SEP patients. Relapse rates were higher in SBP (65%) compared to patients with SEP (18%) (P < .01). Only one in-field relapse was identified for the whole series. Ten- and 15-year overall survival, progression free survival (PFS) and multiple myeloma free survival (MMFS) for patients with SBP were 60%/41%, 25%/17%, and 33%/33%. Corresponding values for patients with SEP were 67%/54%, 57%/44%, and 91%/91%. SBP patients had significantly shorter PFS and MMFS compared to SEP patients (P < .01 for both). Only two of the SEP patients developed multiple myeloma and no patient in the whole series progressed to multiple myeloma later than 10 years after diagnosis. Unlike for SEP, the major cause of death among SBP patients was multiple myeloma (49%). Compared to matched normal population, no increased risk of death from secondary malignancies or cardiovascular disease was observed. Positive predictors in SBP patients were for overall survival age <60 years, combined laminectomy and radiotherapy and radiotherapy dose >40 gray, for PFS tumour size <6 cm and combined laminectomy and radiotherapy and for MMFS tumour size <6 cm. Radiotherapy confers excellent local control in both SEP and SBP patients; however, the challenge is to prevent development of multiple myeloma in patients with SBP.

show abstract

Section: Discussioncontrasting

confidence: 84%

Long‐term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population‐based, single‐center study with median follow‐up of 13.7 years

Barzenje

Kolstad

Holte

2017

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Although the optimal dose is still the subject of controversy, in the available reports, it ranged from 40 to 60 Gy. Similarly, in this study, the median applied dose was 56 Gy [2][3][4][5]7,12,[14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 83%

Effect of definitive radiotherapy on the long-term outcome in patients with solitary extramedullary plasmacytoma

Skóra

Pudełek²,

Nowak-Sadzikowska

et al. 2015

Hematological Oncology

View full text Add to dashboard Cite

Extramedullary solitary plasmacytoma (EMP) is a rare type of malignancy. This paper presents a retrospective review of the experience with EMP at the Krakow Oncology Center. Records of 17 patients with head and neck EMP, treated with definitive radiotherapy between 1976 and 2009, were analyzed. The total tumour dose ranged from 45 to 70 Gy (median 56 Gy). In four patients with partial response after radiotherapy, adjuvant melphalan-based chemotherapy was applied. The median follow-up period was 8.6 years. The treatment was well tolerated. The estimated 10-year overall survival, disease-free survival, and multiple myeloma-free survival were 68.4%, 49.3%, and 55%, respectively. The 10-year local control rate was 90.9%. No in-field local recurrence was observed. During the follow-up, progression into multiple myeloma was observed in five patients, with a mean time to conversion of 24 months. The only factor adversely affecting overall survival on univariate analysis was the age >56 years, whereas a complete tumour regression after radiotherapy was associated with a significant improvement in both disease-free survival and multiple myeloma-free survival. Despite the high effectiveness of local radiotherapy, there is still a significant treatment failure risk due to the EMP conversion into generalized disease. An attempt to identify prognostic factors may facilitate selection of patients with a high risk of progression to multiple myeloma. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

“…Although highly radiosensitive, radiotherapy to a large retroperitoneal plasmacytoma is associated with significant morbidity 5. Current literature supports use of radiotherapy11 12 or combined radiotherapy and surgery depending on the resectability of the tumour7 13 or combined radiotherapy and chemotherapy 14. Usual chemotherapy regimens suggest use of bortezomib as one of the newer agents or lenalidomide along with dexamethasone.…”

Section: Discussionmentioning

confidence: 99%

A case of disseminated recurrent retroperitoneal plasmacytoma with left obstructive hydronephrosis

et al. 2014

View full text Add to dashboard Cite

Retroperitoneal extramedullary plasmacytoma (EMP) is a rare condition that often poses a diagnostic challenge. This is mainly due to its unusual location and non-specific symptoms especially in its early stages. Retroperitoneal plasmacytoma with renal involvement is an extremely rare entity and to date, less than 25 cases have been reported in the literature. We describe a case of a 65-year-old woman with primary retroperitoneal plasmacytoma, confirmed by ultrasound-guided biopsy and histopathological examination, with unilateral left obstructive hydronephrosis and metastasis to the lungs. Our patient was started on chemotherapy to which she did not respond. Subsequently, she resorted to palliative measures. Our case highlights key aspects of clinical presentation, diagnosis and treatment options available for management of retroperitoneal plasmacytoma.

show abstract

Radiotherapy of solitary plasmacytoma

Cited by 26 publications

References 19 publications

Long‐term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population‐based, single‐center study with median follow‐up of 13.7 years

Long‐term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population‐based, single‐center study with median follow‐up of 13.7 years

Effect of definitive radiotherapy on the long-term outcome in patients with solitary extramedullary plasmacytoma

A case of disseminated recurrent retroperitoneal plasmacytoma with left obstructive hydronephrosis

Contact Info

Product

Resources

About